Orthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M Toward a Pioneering Drug for BK Virus

Orthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M Toward a Pioneering Drug for BK Virus Published: Jul 24, 2023 In an exciting development, Orthogon Therapeutics LLC, a leading player in the field of antiviral therapeutics, has achieved a significant breakthrough. The company's flagship molecule has successfully completed acute toxicity studies, marking a majo..

  • format_list_bulleted BS
  • · 2023. 7. 24.
  • textsms

Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

Harbour BioMed, a global biopharmaceutical company, has announced that the National Medical Products Administration (NMPA) of China has accepted its Biologics License Application (BLA) for batoclimab in the treatment of generalized myasthenia gravis (gMG). This marks the first BLA accepted by NMPA since Harbour BioMed's establishment. Batoclimab is an innovative therapy targeting anti-FcRn treat..

  • format_list_bulleted BS
  • · 2023. 7. 2.
  • textsms